Description
| Product Name | CAT.No | Details |
| PKU | BXC0810A | 200T |
Product Description
The Biorex Diagnostics Neonatal PKU (Phenylketonuria) Test is a high-quality screening assay developed for the early detection of PKU in newborns. PKU is a rare inherited metabolic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, which leads to elevated levels of phenylalanine in the blood. Early identification is essential, as timely dietary intervention can prevent severe neurological damage, developmental delays, and other long-term complications. This assay provides a simple, reliable, and highly sensitive method for accurately detecting elevated phenylalanine levels, making it ideal for clinical laboratories, hospitals, and national newborn screening programmes.
Key Features
- Newborn-Focused Sampling: Compatible with heel-prick dried blood spots, allowing minimally invasive testing suitable for infants.
- Quantitative Measurement: Accurately detects phenylalanine levels, enabling precise identification of infants at risk for PKU.
- Rapid and Reliable Results: Provides reproducible measurements quickly, supporting timely clinical decision-making and dietary intervention.
- High Sensitivity and Specificity: Capable of detecting even mild elevations of phenylalanine, ensuring early and accurate diagnosis.
- User-Friendly Workflow: Streamlined procedures and ready-to-use reagents allow efficient high-throughput neonatal screening.
- Laboratory Integration: Supports LIMS connectivity and compatibility with standard platforms, facilitating seamless data management.
- Cost-Effective Solution: Designed for large-scale screening initiatives, providing accurate neonatal testing at an economical price.
Benefits
The Biorex Neonatal PKU Test offers a trusted and clinically relevant solution for early detection of phenylketonuria. Its precise, reproducible, and user-friendly design allows healthcare providers to implement dietary interventions promptly, reducing the risk of irreversible neurological damage. The assay’s robust methodology and scalable workflow make it suitable for both routine hospital testing and large-scale newborn screening programmes.
With its combination of accuracy, reliability, and operational efficiency, the Biorex Neonatal PKU Test ensures that at-risk infants are identified promptly, laboratories maintain high-quality performance, and clinical teams can deliver optimal patient care. This makes the assay an indispensable tool for newborn metabolic screening and early PKU management.
Contact Us for more information.